🔎 Trials Near Me

Home › Triple-Negative Breast Cancer › Florida › Tampa

Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Tampa, FL

Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Tampa. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Study of AVZO-021 in Patients With Advanced Solid Tumors

Nagre-recruitPhase 1/2
  • Avenzo Therapeutics Recruiting Site, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05867251

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Nagre-recruitObservasyonal na pag-aaral
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04981119

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Nagre-recruitPhase 2
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05528133

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Nagre-recruitPhase 1
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07020117

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Nagre-recruitPhase 2
  • Moffitt Cancer Center-International Plaza, Tampa
  • Moffitt Cancer Center - McKinley Campus, Tampa
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT03606967

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Nagre-recruitPhase 1/2
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT05377996

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Nagre-recruitPhase 1
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT05076760

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Nagre-recruitPhase 2
  • H. Lee Moffitt Cancer Center and Research Institute, Tampa
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT01042379

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Nagre-recruitMaagang Phase 1
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 1, 2026 · NCT06435351

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Nagre-recruitPhase 1
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT05504707

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Nagre-recruitPhase 1/2
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 5, 2025 · NCT06238921

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Nagre-recruitPhase 1/2
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT06682793

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Nagre-recruitPhase 2
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 19, 2025 · NCT06568692

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Nagre-recruitPhase 1/2
  • Moffitt Cancer Center, Tampa
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 15, 2024 · NCT04787042

Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod

Iba pang pag-aaral sa Tampa

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.